Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
Primary Purpose
Coagulopathy
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Thromboelastography (TEG 6S)
Sponsored by
About this trial
This is an interventional diagnostic trial for Coagulopathy focused on measuring thromboelastography
Eligibility Criteria
Inclusion Criteria: -Patients less than 18 years of age undergoing elective pediatric surgical care in the operating room at Riley Hospital for Children Exclusion Criteria: Known disorder of coagulation pathway(s) Administration of medications that may alter the coagulation cascade Patients in foster care or wards of the court
Sites / Locations
- Riley Hospital for ChildrenRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Pediatric Participants
Arm Description
Pediatric surgery patients undergoing elective pediatric surgical cases under anesthesia will be invited to participate in this prospective laboratory test validation study. The results of the interventional test will not be used in clinical decision making for the participant.
Outcomes
Primary Outcome Measures
TEG 6s viscoelastic measurement, angle, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
TEG 6s viscoelastic measurements, R time, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
TEG 6s viscoelastic measurement, maximum amplitude, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
TEG 6s viscoelastic measurement, lysis at 30 minutes, in pediatric surgical patients
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05874843
Brief Title
Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
Official Title
Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 11, 2023 (Actual)
Primary Completion Date
November 30, 2023 (Anticipated)
Study Completion Date
November 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this observational study is to learn about the performance of the TEG6s in normal pediatric patients. The main questions it aims to answer are: What are the normal TEG 6S lab results in normal pediatric patients and how do they compare to existing published reference ranges. Participants and their guardians will be asked to submit a small amount of blood at the beginning of an elective operation for analysis in the TEG 6s machine.
Detailed Description
Trauma is the leading cause of death in children. Researchers, starting with Trunkey et al., have described three general time points of mortality after trauma - in the field, early secondary to hemorrhage and late due to infectious complications. Early mortality after trauma is specifically linked to hemorrhage. Trauma-induced coagulopathy is a multifactorial phenomenon present after trauma in both children and adults that can worsen hemorrhage and ultimately lead to increased mortality. Classical laboratory measurements of the coagulation pathway (PT, PTT, INR, fibrinogen, platelet count) have shown derangement after trauma and are correlated with mortality. However, these traditional tests of coagulation function take time to run as they are drawn and sent to a laboratory for evaluation and therefore provide a delayed snapshot of a potentially evolving coagulopathy scenario. Adult trauma centers have increasingly incorporated viscoelastic measures of the coagulation cascade to evaluate for and subsequently treat trauma-induced coagulopathy. One such test is thromboelastography (TEG) which is a whole blood assay that assesses functional clot kinetics and stability. It provides information on how various hemostatic factors, including coagulation factors, platelets, and fibrinogen, contribute to the clot. A 2016 randomized-controlled trial in adult trauma patients who met criteria for the institutions massive transfusion protocol were randomized to transfusion guided by TEG or by conventional measure of coagulopathy. The authors found increased survival in the TEG group as well as less transfusion of platelets and fresh frozen plasma.
TEG assesses the clot rate, clot strength, and clot stability, which then assists the clinician in choosing appropriate blood component therapy. The American College of Surgeons Trauma Quality Improvement Program recommends the use of thromboelastography when patients are at risk for trauma-induced coagulopathy. Visicoeslastic evaluation of the coagulation pathway has become the standard of care in adult trauma patients to provide information on a patient's coagulation status, particularly when the patient is requiring multiple blood products. This allows the physician to deliver a targeted hemostatic resuscitation appropriate for the patient needs in real-time. This can result in a decrease of blood products and quicker reversal of the trauma induced coagulopathy.
Riley Hospital for Children at IU Health has a TEG 5000 machine (Haemonetics Corp.) which performs the coagulation tests needed to help guide the resuscitation of a critical trauma patient. While an improvement over previous tests (such as INR, platelet count, PTT), the TEG 5000 still takes 45-60 minutes to get the results needed to guide fluid/blood resuscitation, making the results outdated as the patient has potentially received multiple units of blood products and/or had additional bleeding during that time. The TEG 5000 machine also has very specific environmental, and preparation needs (i.e. flat surface which is not bumped; controlled pipetting (dropping) of blood products into machine as well as mixing of reagents) that is very difficult to do in a busy trauma bay/emergency department with a critical patient.
The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing. The sample is drawn automatically into the testing chambers rather than requiring manual pipetting, leading to less user variability. This simpler operation provides results in 15-20 minutes, making the test more clinically useful in guiding transfusion therapy during active bleeding.
TEG 6s and TEG 5000 have been evaluated in adult patients with good agreement between the modalities. More specifically, the TEG 6s has been validated in adult trauma patients. However, few pediatric studies exist.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coagulopathy
Keywords
thromboelastography
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Pediatric Participants
Arm Type
Other
Arm Description
Pediatric surgery patients undergoing elective pediatric surgical cases under anesthesia will be invited to participate in this prospective laboratory test validation study. The results of the interventional test will not be used in clinical decision making for the participant.
Intervention Type
Diagnostic Test
Intervention Name(s)
Thromboelastography (TEG 6S)
Intervention Description
The TEG 6s assays are performed in a microfluidic cartridge which only requires a small amount of a patient's blood be transferred to the cartridge for analysis. The vibration frequency of the blood meniscus at which resonance occurs is used to create a clot dynamics tracing.
Primary Outcome Measure Information:
Title
TEG 6s viscoelastic measurement, angle, in pediatric surgical patients
Description
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Time Frame
2 months
Title
TEG 6s viscoelastic measurements, R time, in pediatric surgical patients
Description
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Time Frame
2 months
Title
TEG 6s viscoelastic measurement, maximum amplitude, in pediatric surgical patients
Description
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Time Frame
2 months
Title
TEG 6s viscoelastic measurement, lysis at 30 minutes, in pediatric surgical patients
Description
To validate the TEG 6S measurement values in pediatric patients by comparing its viscoelastic values with those existing published reference ranges
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
3 Months
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
-Patients less than 18 years of age undergoing elective pediatric surgical care in the operating room at Riley Hospital for Children
Exclusion Criteria:
Known disorder of coagulation pathway(s)
Administration of medications that may alter the coagulation cascade
Patients in foster care or wards of the court
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Matthew Landman, MD, MPH
Phone
317-944-4681
Email
landman@iu.edu
Facility Information:
Facility Name
Riley Hospital for Children
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthew Landman, MD
Phone
317-944-4681
Email
landman@iu.edu
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients
We'll reach out to this number within 24 hrs